Founded Year

2015

Stage

Series B | Alive

Total Raised

$31.3M

About Holmusk

Holmusk is a data science and digital therapeutics company with a global presence that is dedicated to establishing objective evidence as a core utility to the treatment of mental health and chronic diseases. Holmusk's proprietary technology powers data-driven medicine that leverages analytic and digital tools to address the unmet need in healthcare and pharma-life science.

Holmusk Headquarter Location

71 Ayer Rajah Crescent #06-07/08/09

139951,

Singapore

+65-6250-4233

ESPs containing Holmusk

The ESP matrix leverages data and analyst insight to identify and rank leading companies in a given technology landscape.

EXECUTION STRENGTHMARKET STRENGTHLEADERHIGHFLIEROUTPERFORMERCHALLENGER
Life Sciences / Biopharma Tech

Companies in this market offer alternative datasets that can supplement clinical trial data and improve the likelihood of trial success. These companies collect data from a variety of sources, such as patient registries, EHRs, insurance databases, social media, and patient research networks.

Holmusk named as Highflier among 15 other companies, including Datavant, Syapse, and Evidation.

Predict your next investment

The CB Insights tech market intelligence platform analyzes millions of data points on venture capital, startups, patents , partnerships and news mentions to help you see tomorrow's opportunities, today.

Holmusk's Products & Differentiation

See Holmusk's products and how their products differentiate from alternatives and competitors

  • NeuroBlu

    NeuroBlu democratizes access to one of the largest and deepest research-grade, real-world datasets in behavioral health enabling new dimensions of exploration and insight generation for the life sciences industry, academia, and regulators alike.

  • Subscribe to see more

    We're on a mission to enable every organization to make smarter decisions about tech. Whether it's finding a new game-changing vendor or understanding a new market, it's easier, faster and smarter with CB Insights. All made possible by the smartest, hardest-working team in tech. Subscribe to see more.

  • Subscribe to see more

    We're on a mission to enable every organization to make smarter decisions about tech. Whether it's finding a new game-changing vendor or understanding a new market, it's easier, faster and smarter with CB Insights. All made possible by the smartest, hardest-working team in tech. Subscribe to see more.

  • Subscribe to see more

    We're on a mission to enable every organization to make smarter decisions about tech. Whether it's finding a new game-changing vendor or understanding a new market, it's easier, faster and smarter with CB Insights. All made possible by the smartest, hardest-working team in tech. Subscribe to see more.

  • Subscribe to see more

    We're on a mission to enable every organization to make smarter decisions about tech. Whether it's finding a new game-changing vendor or understanding a new market, it's easier, faster and smarter with CB Insights. All made possible by the smartest, hardest-working team in tech. Subscribe to see more.

Research containing Holmusk

Get data-driven expert analysis from the CB Insights Intelligence Unit.

CB Insights Intelligence Analysts have mentioned Holmusk in 2 CB Insights research briefs, most recently on Jun 2, 2022.

Expert Collections containing Holmusk

Expert Collections are analyst-curated lists that highlight the companies you need to know in the most important technology spaces.

Holmusk is included in 8 Expert Collections, including Digital Health.

D

Digital Health

13,495 items

Companies developing and enabling evidence-based, software-driven therapeutic interventions to prevent, manage, or treat a medical disorder or disease. (*Scope follows the Digital Therapeutics Alliance definition)

M

Mental Health Tech

1,223 items

This collection includes companies applying technology to problems of emotional, psychological, and social well-being. Examples include companies working in areas such as substance abuse, eating disorders, stress reduction, depression, PTSD, and anxiety.

C

Clinical Trials Tech

329 items

Companies developing products and services to streamline drug R&D, from drug discovery, pre-clinical testing, and clinical trials.

A

Artificial Intelligence

9,093 items

This collection includes startups selling AI SaaS, using AI algorithms to develop their core products, and those developing hardware to support AI workloads.

B

Biopharma Tech

5,567 items

Companies involved in the research, development, and commercialization of chemically- or biologically-derived therapeutic & theranostic drugs. Excludes vitamins/supplements, CROs/clinical trial services.

D

Diabetes

1,750 items

Latest Holmusk News

Prevalence of anxiety, depression in U.S. adults elevated in first year of pandemic

Jun 22, 2022

Disclosures: Kessler reports receiving personal fees from Datastat Inc., Holmusk, RallyPoint Networks Inc., and Sage Therapeutics, and reported holding stock options in Mirah, PYM and Roga Sciences during the conduct of the study. Please see the study for all other authors’ relevant financial disclosures. ADD TOPIC TO EMAIL ALERTS Receive an email when new articles are posted on Please provide your email address to receive an email when new articles are posted on . Please try again later. If you continue to have this issue please contact customerservice@slackinc.com . Back to Healio Prevalence of clinically significant anxiety and depression among adults in the United States increased during the first year of the COVID-19 pandemic compared with prior years, according to a study published in JAMA Network Open. “Concerns about adverse mental health effects of COVID-19 have been raised since the beginning of the pandemic,” Ronald C. Kessler, PhD, of the department of health care policy at Harvard Medical School, and colleagues wrote. “Many empirical papers subsequently investigated the association of the pandemic with mental health, and most concluded that the pandemic cause dramatic increases in anxiety and depression.” Source: Adobe Stock. Kessler and colleagues examined survey data for clinically significant diagnoses of anxiety and depression among adults during the first year of the pandemic. The study obtained information from the CDC’s Behavioral Risk Factor Surveillance System (BRFSS), a state-based monthly telephone survey in which 1,429,354 adults responded (1,093,663 from 2017 to 2019; 335,691 from March to December 2020). The primary outcome was estimated 30-day prevalence of anxiety and depression based on a single BRFSS item calibrated to a score of six or higher on the four-item Patient Health Questionnaire. Results showed that median within-state response rates were 45.9% to 49.4% in during the 2017 to 2019 survey period, and 47.9% in 2020. Estimated 30-day prevalence of clinically significant anxiety and depression was 0.4 (95% CI, 0 to 0.7) percentage points higher in March to December 2020 (12.4%) than March to December 2017 to 2019 (12.1%). This estimated increase was limited, however, to students (2.4 [95% CI, 0.8 to 3.9] percentage points) and the employed (0.9 [95% CI, 0.5 to 1.4] percentage points). “Although it is impossible to predict future trends with accuracy there are some promising signs in the expansion of tele-mental health care and increased use of scalable interventions to address increasing demand for treatment of emotional problems,” Kessler and colleagues wrote. Read more about

Holmusk Web Traffic

Rank
Page Views per User (PVPU)
Page Views per Million (PVPM)
Reach per Million (RPM)
CBI Logo

Holmusk Rank

  • When was Holmusk founded?

    Holmusk was founded in 2015.

  • What is Holmusk's latest funding round?

    Holmusk's latest funding round is Series B.

  • How much did Holmusk raise?

    Holmusk raised a total of $31.3M.

  • Who are the investors of Holmusk?

    Investors of Holmusk include Heritas Capital, Health Catalyst Capital Management, Optum Ventures, dRx Capital, Northwell Holdings & Ventures and 5 more.

  • Who are Holmusk's competitors?

    Competitors of Holmusk include Syapse, Fitterfly, Feel Therapeutics, Owkin, Osmind, Sidekick Health, Mendel.ai, ConcertAI, Dr.Diary, Omada Health and 45 more.

  • What products does Holmusk offer?

    Holmusk's products include NeuroBlu and 4 more.

  • Who are Holmusk's customers?

    Customers of Holmusk include AIA, Otsuka and Mersey Care NHS Foundation Trust.

You May Also Like

Glooko Logo
Glooko

Glooko's universal diabetes software products provide insights to improve outcomes for people with diabetes and their care teams. Glooko's systems synchronize data from more than 190 diabetes devices and activity trackers, and they deliver integrated, timely and useful patient data, including glucose levels, blood pressure, weight, and food, insulin and medication intake.

Virta Health Logo
Virta Health

Virta Health develops a clinically-proven treatment to safely and sustainably reverse type 2 diabetes and other chronic metabolic diseases without the use of medications or surgery.

Vida Health Logo
Vida Health

Vida Health is a virtual care company that combines a human-centric approach with technology to address chronic physical and behavioral health conditions. The company provides personalized digital therapeutic programs combined with real human health coaching & therapy through a mobile & online platform that supports individuals in managing & reversing conditions such as diabetes, hypertension, obesity, depression, anxiety, stress, asthma, & more. The platform integrates individual expert care with machine learning & remote monitoring to deliver lasting behavior change, health outcomes & cost savings.

Second Nature Logo
Second Nature

Second Nature is a health technology start-up that helps people lessen the symptoms of type 2 diabetes. Second Nature sends customers an activity tracker and wireless scales, and appoints them a mentor to guide them through lifestyle changes over a six-week program that makes diet recommendations, sets goals, and keeps the user motivated in an effort to help prevent people with pre-diabetes from developing type 2 diabetes.

Sweetch Health Logo
Sweetch Health

Sweetch Health increases users’ adherence to essential health promotion, disease prevention and management recommendations in a personalized, cost-efficient, and scalable way. Sweetch’s Just-in-Time Adaptive Intervention technology presents the user just-in-time, just-in-place recommendations that are automatically and continuously optimized based on the user’s current context and past compliance patterns in a way that increases the likelihood of action.

Canary Health Logo
Canary Health

Canary Health is a provider of digital health self-management programs which includes a CDC approved online diabetes prevention program and a chronic disease self-management program.

Discover the right solution for your team

The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.

Request a demo

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.